FRE Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.…
Industry Peers
Medical Care FacilitiesKey Statistics
About Fresenius (ETR: FRE)
›
Fresenius (ETR: FRE) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 179,493 employees.
The shares were at 50.49 EUR on 20 November 2026, up 6.0% over 52 weeks. Its 52-week range is 35.11 EUR to 54.64 EUR: the price is 7.6% below the high and 43.8% above the low.
At a market capitalisation of 29.16B EUR, it trades at 18.4 times trailing earnings and 13.2 times forward earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 23.7, a discount of 22% for FRE. It pays a dividend yielding 1.95% (it pays out 37% of its earnings), against a median of 0.66% among the dividend payers in that peer group.
Fresenius reports return on equity of 6.6%, an operating margin of 9.9% and revenue up 5.9% year over year.
Its debt exceeds its cash by 10.12B EUR, a debt-to-equity ratio of 0.62. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 58.19 EUR is 15.3% above the current price. The next earnings report is expected on 24 February 2027.